TriangleOlutasidenib + TMZ (NCT06161974)
Olutasidenib + TMZ trial for High Grade Glioma (NCT06161974). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for patients aged 12–39, weighing at least 35 kilograms, with newly diagnosed, nonmetastatic high-grade glioma carrying specified IDH1 mutations. IDH2-mutated tumors and oligodendroglioma are excluded.
The idea: after radiation, oral olutasidenib blocks mutant IDH1, while temozolomide damages tumor DNA. Treatment combines both drugs for 13 cycles, then olutasidenib alone for 13 cycles. Tumor tissue is required; an initial feasibility group tests dosing. Researchers measure progression-free survival.
This phase 2 study plans 60 patients. Rigel Pharmaceuticals sponsors it; six US sites are recruiting.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.